PER-009-08已完成未知
PREDICTION OF RESPONSE AND TOXICITY IN PATIENTS WHO RECEIVE PACLITAXEL AND AVASTIN FOR BREAST CANCER. A CORRELATIVE, MULTICENTRIC, GENOMIC, PROTEOMIC AND PHARMACOGENIC STUDY
HOSSIER ONCOLOGY GROUP,0 个研究点目标入组 0 人开始时间: 2008年10月27日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- •Written informed consent and HIPAA authorization to release personal health information.
- •Planned chemotherapy regimen with placitaxel and Avastin for the treatment of metastatic breast cancer of the patient.
- •ECOG functional status scale from O to 1.
- •Histological and cytologic confirmation of breast adenocarcinoma with measurable, locally recurrent, locally advanced disease (which is not receptive to resection with curative intent), or metastatic.
- •Total neutrophil count> 1200 / mm3
- •Platelet count> 100,000 / mm3
- •Total bilirubin <1.5 mg / dL
- •SGOT (AST) <2x of normal upper limit (<5x of normal upper limit in patients with known liver involvement)
- •PTT <1.5x of normal upper limit
- •INR <1.5x of normal upper limit
- •Women of 18 years.
- •Patients must agree to have a biopsy performed to obtain fresh tissue or can identify a block of FFPE tissue in which tissue samples can be obtained to complete the test for this study.
排除标准
- •Patients must not have had chemotherapy for locally recurrent or metastatic breast cancer.
- •Hormone therapy for locally recurrent or metastatic disease must have been discontinued at least 2 weeks before entry into the study.
- •Patients should not have had adjuvant or neoadjuvant taxane therapy within 12 months before entry into the study.
- •Patients with breast cancer HER-2 overexpression (gene amplification by FISH or overexpression 3+ by immunohistochemistry) are not eligible unless they have received prior therapy with Herceptin.
- •Patients should not have had a major surgical procedure within 4 weeks prior to entering the study, (placement of vascular access device, breast biopsy, will not be considered major surgery.)
- •Patients should not have had a minor surgical procedure, access device placement, or fine needle aspiration within 7 days of initiating protocol therapy.
- •Patients must not have received radiation within 2 weeks before entering the study, xx O´IW.
- •The previously irradiated area (s) should not be the only place of illness for study entry.
- •Patients should not have a history of bleeding diathesis or have had anticoagulant therapy within 10 days prior to study entry, (low-dose anticoagulant therapy is allowed to maintain evidence of a vascular access device.)
- •Patients with a prior history of deep vein thrombosis or pulmonary embolism are not eligible.
- •Use of aspirin (> 325 mg / day) or another nonsteroidal anti-inflammatory drug known to inhibit platelet function daily is not allowed within 10 days of study entry.
- •Patients who are using any of the medications known to inhibit platelet function are not eligible; dipiridamole (Persantine), ticlopidine (Ticlid), clopidogrel (Plavix) and cilostazol (Pietal).
- •Clinically significant cardiovascular or cerebrovascular disease including previous myocardial infarction (within 6 months prior to study entry), unstable angina, Grade II or greater peripheral vascular disease, Grade II congestive heart failure or greater according to the Heart Association of New York City (NYHA), hypertensive crisis, hypertensive encephalopathy or uncontrolled hypertension (PS> 150, PD> 100).
- •Patients should not have a history of TIA (Transient Ischemic Attack) or CVA (Vascular Brain Injury) within 6 months prior to the study.
- •Patients should not have a history of radiological evidence of CNS metastasis including brain lesions previously treated, extracted or asymptomatic or leptomeningeal compromise (a CT or MRI should be obtained within 6 months prior to study entry)
- •Patients should not have a wound or fracture that does not heal.
- •Patients should not have hypersensitivity to placitaxel or to medications that use Cremophor as a vehicle, Chinese hamster ovarian cell products or other recombinant human antibodies.
- •Women should not be pregnant or breastfeeding.
- •Women of childbearing age should use an accepted and effective method of contraception (hormonal or barrier method of birth control, abstinence) while on treatment and for a period of 3 months thereafter.
- •Women of childbearing age should use a negative pregnancy test within 7 days prior to their registration for protocol therapy. Patients are not considered to have fertile potential if they have been surgically sterilized (they have had a hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or are menopausal.
研究者
相似试验
已完成
不适用
PREDICTION OF RESPONSE AND TOXICITY IN PATIENTS WHO RECEIVE CHEMOTHERAPY FOR BREAST CANCER, CORRELATIVE STUDY OF GENOMICS, PROTEOMICS AND PHARMACOGENOMY-C509 Breast, unspecifiedBreast, unspecifiedC509PER-079-05HOSSIER ONCOLOGY GROUP,
已完成
不适用
Prediction of the therapeutic response and adverse events to methotrexate by monitoring methotrexate-polyglutamates (MTX-PGs) concentration in erythrocytes in Japanese patients with rheumatoid arthritis (RA).Rheumatoid arthritisJPRN-UMIN000020134Jichi Medical University56
尚未招募
2 期
High dose radiotherapy in the treatment of advanced carcinoma cervix -a prospective studyCTRI/2023/07/055597Dr Anjan Bera
招募中
不适用
Prediction of therapy response and treatment outcomes in early course of schizophrenia.Subproject D1_AP2 of the research network ESPRIT (Enhancing Schizophrenia Prevention and Recovery through Innovative Treatments)DSM IV-TR:295.10-30, 295.90: Schizophrenia High Risc State of transmission to psychosisDRKS00010936Klinik und Poliklinik für Psychiatrie und Psychotherapie,LVR-Klinikum Düsseldorf / Kliniken der Heinrich Heine Universität Düsseldorf600
已完成
不适用
Prediction of outcomes and response to treatments with an ultrasensitive method for assessing intratumor epigenetic heterogeneity in colorectal cancerColorectal cancerJPRN-UMIN000021191Juntendo University Faculty of Medicine60